Version history

{
  "session_id": "sess_SDA-2026-04-12-gap-pubmed-20260410-184126-b2c3e2e8_20260412-192103",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Addressing the APOE4 Paradox: A Translational Assessment\n\n## Framing the Core Problem\n\nThe paradox is genuine and mechanistically important. APOE4's association with improved outcomes in sepsis (PMID: 25386936), bacterial meningitis (PMID: 24092790), hepatitis C (PMID: 15939837), and COVID-19 (PMID: 32641583) isn't marginal noise—these effects are consistent across pathogen classes and cohorts. Any viable hypothesis must explain how the *same* variant can be simultaneously immunoprotective and neurotoxic. This isn't a mere inconsistency; it's a clue to AD pathogenesis that the field has insufficiently exploited.\n\n---\n\n## The 2-3 Hypotheses with Highest Translational Potential\n\n### Hypothesis 1 (Highest Priority): *Compartmentalized Immune Privilege—Beneficial Periphery, Pathological Brain*\n\n**Core claim:** APOE4's immune activation is appropriate in the peripheral compartment, where immune resolution mechanisms exist and antigen exposure is transient. In the CNS, these same signals become chronic because: (a) amyloid itself acts as a持续性免疫 activator, (b) microglia are post-mitotic and cannot \"resolve\" by dilution, and (c) the blood-brain barrier limits peripheral immune resolution from accessing the site.\n\n**Translational potential:** This hypothesis generates immediately testable therapeutic predictions: *timed, short-course* immune modulation rather than chronic immunosuppression, with the goal of preventing the transition",
  "tokens_used": "362"
}